KEROS THERAPEUTICS INC (KROS)
US4923271013 - Common Stock
Notable Thursday Option Activity: KROS, AMKR, SQ
Which stocks are moving on Thursday?
Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session.
What's going on in today's session
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
RSI Alert: Keros Therapeutics (KROS) Now Oversold
These stocks are gapping in today's session
Thursday's session: gap up and gap down stocks
Keros Therapeutics Plummets 73% On Unexpected Side Effects In Hypertension Study
The company is continuing to test the lowest dose of its pulmonary arterial hypertension drug.
Stay updated with the stocks that are on the move in today's pre-market session.
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Keros Plunges After Dosing Halted in Lung Drug Trial on Safety
Keros Therapeutics Inc. shares plunged after the biotech company halted dosing for some patients in a mid-stage trial of its lung disorder drug over side effect concerns.
Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial
Keros will host an update call and webcast today, December 12, 2024, at 8:00 a.m. ET LEXINGTON, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Keros...
Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition
Elritercept demonstrated a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden,...
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
LEXINGTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage...
Interesting KROS Put And Call Options For April 2025
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage...
Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark
Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86.
First Week of October 18th Options Trading For Keros Therapeutics (KROS)
Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial
LEXINGTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage...
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
LEXINGTON, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage...
KROS Stock Earnings: Keros Therapeutics Misses EPS for Q2 2024
KROS stock results show that Keros Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
KROS Stock Earnings: Keros Therapeutics Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Keros Therapeutics (NASDAQ:KROS) just reported results for the second quarter o...
Keros Therapeutics Reports Second Quarter 2024 Financial Results
LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage...
KROS Crosses Above Key Moving Average Level
Keros Therapeutics (KROS) Shares Cross Above 200 DMA
First Week of KROS August 16th Options Trading
Keros Therapeutics is Now Oversold (KROS)
Keros Therapeutics Announces Leadership Updates
LEXINGTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical...
Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association
Elritercept continued to demonstrate a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high...
Keros Therapeutics to Host a Corporate Update Conference Call and Webcast
LEXINGTON, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical...
Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors
LEXINGTON, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical...